Senator Seeks Answers on Federal Scrutiny of the Dialysis Sector

A prominent senator is pushing federal officials for transparency regarding an inquiry into the dialysis market, amid claims that a tight control by two main companies is degrading crucial kidney treatment.

In the U.S., two firms dominate, controlling about 75% of dialysis facilities—totalling roughly 5,600 outlets. Senator Richard Blumenthal, a Democrat from Connecticut, expressed concern over potential misuse of market power.

"The federal government may feel powerless against these companies that nearly monopolize dialysis care," Blumenthal stated in his discussion with CBS News. "Nonetheless, there is a lack of action in exploiting antitrust laws."

Federal Trade Commission's Market Evaluation

The FTC has been examining whether the domination by these two companies negatively affects patient outcomes, Blumenthal mentioned. However, the results remain undisclosed. The senator urged that decisive actions are needed to fix identified issues and safeguard patients, especially veterans.

Dialysis serves as a lifeline for approximately 500,000 Americans battling end-stage kidney disease while awaiting transplants. Critics suggest the top providers, Fresenius and DaVita, prioritize profits at the expense of patient care.

Industry Critique and Responses

Tom Mueller, who authored a book analyzing the industry, likened it to emergency care being offered in a retail setting, with patients receiving suboptimal personalized treatment.

According to academic Ryan McDevitt, these two firms have maneuvered towards a duopoly over decades, creating the nation’s most concentrated healthcare sector.

Investigative Findings and Company Reactions

Reports indicated that roughly one-third of dialysis facilities fell short of national standards this year, with average compliance scores low. Meanwhile, both Fresenius and DaVita defended their records, citing consistent exemplary care.

McDevitt pointed out that Medicare’s financial reimbursement strategies might drive facilities to prioritize profits over care. However, both companies contest these assertions.

Revenue Insights and Patient Impacts

In the previous year, DaVita performed numerous treatments earning substantial revenue, while combined, DaVita and Fresenius saw revenues of $33.7 billion. Observations suggest that acquired independent clinics by these giants exhibit declining patient survival rates and increased hospitalizations and infection incidents.

Statements from Fresenius and DaVita

Both Fresenius and DaVita have rebutted criticisms. Fresenius asserts its continuous focus on improving patient quality of life, while DaVita maintains its high standard of personalized caregiving.

Routine appraisals by CMS revealed over 115,000 infractions since 2013, including inadequate hygiene and training. Despite this, Fresenius claimed a superior star rating compared to other providers nationally, while DaVita described identified issues as rare.

A Call for Regulatory Action

Senator Blumenthal highlighted the reliance of military veterans on these dialysis services, emphasizing the need for rigorous regulatory intervention against potential monopolistic practices within the industry.

In communication with FTC Chairman Andrew Ferguson, Blumenthal stressed the urgency of forceful measures to rectify misuse and protect vulnerable populations, challenging the FTC to address the monopolistic and consumer-unfriendly environment.

Company and Agency Responses

Fresenius acknowledged the ongoing FTC inquiry, pledging full cooperation but refrained from further public comment. As of yet, neither DaVita nor the FTC has issued a statement regarding the investigation.